Related Experiment Video

Updated: May 6, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

Molecularly targeted drugs for metastatic colorectal cancer

Ying-dong Cheng1, Hua Yang, Guo-qing Chen

  • 1Department of General Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing, People's Republic of China.

Drug Design, Development and Therapy
|November 9, 2013
PubMed

Insights

Molecularly targeted drugs significantly improve survival rates for metastatic colorectal cancer (mCRC) patients. These targeted therapies offer improved outcomes and potentially lower toxicity compared to traditional chemotherapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Metastatic colorectal cancer (mCRC) presents significant treatment challenges.
  • Traditional chemotherapy has limitations in efficacy and toxicity.
  • Molecularly targeted therapies offer a more precise approach to cancer treatment.

Purpose of the Study:

  • To review recent clinical information on molecularly targeted therapy for mCRC.
  • To focus on US Food and Drug Administration-approved targeted drugs for mCRC.
  • To summarize advancements in mCRC treatment strategies.

Main Methods:

  • Review of recent clinical data and studies on targeted therapies for mCRC.
  • Focus on FDA-approved molecularly targeted drugs.
  • Analysis of treatment outcomes including progression-free and overall survival.

Main Results:

  • Bevacizumab and cetuximab addition to chemotherapy improved progression-free and overall survival in mCRC.
  • Aflibercept combined with FOLFIRI showed improved outcomes.
  • Panitumumab demonstrated significant benefits in wild-type KRAS mCRC patients with FOLFOX or FOLFIRI.
  • Regorafenib is recommended for first- or second-line mCRC treatment with FOLFOX or FOLFIRI.

Conclusions:

  • Molecularly targeted drugs have revolutionized mCRC treatment, improving survival rates.
  • These targeted therapies offer a new era of treatment opportunities for mCRC and other malignancies.
  • The development of selective targeting drugs represents a significant advancement in cancer therapy.
Keywords:
afliberceptantiangiogenic drugbevacizumabcetuximabclinical trialmetastatic colorectal cancer (mCRC)molecularly targeted therapypanitumumabregorafenib

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

9.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.4K